Sunesis Overview

  • Founded
  • 1998
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 8
Employees
  • Latest Deal Type
  • M&A

Sunesis General Information

Description

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Contact Information

Website
www.sunesis.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Viracta
Primary Office
  • 395 Oyster Point Boulevard
  • Suite 400
  • South San Francisco, CA 94080
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sunesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Merger/Acquisition 24-Feb-2021 00000 Completed Generating Revenue
16. Secondary Transaction - Open Market 00000 Completed Generating Revenue
15. PIPE 25-Oct-2017 00000 Completed Generating Revenue
14. Debt - General 01-Apr-2016 0000 00000 Completed Clinical Trials - Phase 1
13. PIPE 01-Jan-2016 00000 Completed Generating Revenue
12. Secondary Transaction - Open Market 01-Jan-2014 00000 Completed Clinical Trials - Phase 1
11. Secondary Transaction - Open Market 00000 Completed Clinical Trials - Phase 1
10. Secondary Transaction - Open Market 31-Dec-2013 00000 Completed Clinical Trials - Phase 1
9. Debt - General 19-Oct-2011 $12M $212M Completed Clinical Trials - Phase 1
8. Secondary Transaction - Open Market 01-Jan-2010 $200M Completed Clinical Trials - Phase 1
To view Sunesis’s complete valuation and funding history, request access »

Sunesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization
Biotechnology
South San Francisco, CA
8 As of 2020
00000
000000&0 00000

00000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000 000000000
Utrecht, Netherlands
000 As of 0000
00000
000000000 00000

00000000

x ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000 000000000
Watertown, MA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sunesis Competitors (107)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merus Formerly VC-backed Utrecht, Netherlands 000 00000 000000000 00000
00000000 000000000 Corporation Watertown, MA 000 00000 000000000 00000
0000000 Formerly PE-Backed Beijing, China 0000 00.000 00000000000 00.000
000000 00000000000 Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
You’re viewing 5 of 107 competitors. Get the full list »

Sunesis Board Members (16)

Name Representing Role Since
James Young Ph.D Self Chairman 000 0000
You’re viewing 1 of 16 board members. Get the full list »

Sunesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sunesis Former Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Venture Capital Minority 000 0000 000000 0
Aisling Capital Venture Capital Minority 000 0000 000000 0
Alta Partners Venture Capital Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
Biogen Corporation Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »

Sunesis Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 24-Feb-2021 0000000 00 Drug Discovery 0000 0000
To view Sunesis’s complete acquisitions history, request access »

Ready to get started?

Request a free trial